2016
Resolving the paradox of randomised controlled trials and observational studies comparing multi-vessel angioplasty and culprit only angioplasty at the time of STEMI
Ahmad Y, Cook C, Shun-Shin M, Balu A, Keene D, Nijjer S, Petraco R, Baker CS, Malik IS, Bellamy MF, Sethi A, Mikhail GW, Al-Bustami M, Khan M, Kaprielian R, Foale RA, Mayet J, Davies JE, Francis DP, Sen S. Resolving the paradox of randomised controlled trials and observational studies comparing multi-vessel angioplasty and culprit only angioplasty at the time of STEMI. International Journal Of Cardiology 2016, 222: 1-8. PMID: 27448698, DOI: 10.1016/j.ijcard.2016.06.106.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLarge observational studiesObservational studyResidual diseaseMulti-vessel coronary artery diseaseHigh mortalityPrimary percutaneous coronary interventionST-elevation myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseReal-world patientsOptimal treatment strategyAllocation biasCoronary interventionCulprit arteryRisk patientsArtery diseaseMyocardial infarctionSmall RCTsWorld patientsTreatment strategiesPatientsEquivalent mortalitySTEMIMortality
2015
A new method of applying randomised control study data to the individual patient: A novel quantitative patient-centred approach to interpreting composite end points
Ahmad Y, Nijjer S, Cook CM, El-Harasis M, Graby J, Petraco R, Kotecha T, Baker CS, Malik IS, Bellamy MF, Sethi A, Mikhail GW, Al-Bustami M, Khan M, Kaprielian R, Foale RA, Mayet J, Davies JE, Francis DP, Sen S. A new method of applying randomised control study data to the individual patient: A novel quantitative patient-centred approach to interpreting composite end points. International Journal Of Cardiology 2015, 195: 216-224. PMID: 26048380, DOI: 10.1016/j.ijcard.2015.05.109.Peer-Reviewed Original ResearchConceptsIndividual patientsComposite end pointCoronary artery bypassDrug-eluting stentsPatient-centered approachSignificant differencesPatient preference dataPatient-centered metricsArtery bypassCardiac catheterisationComposite endpointPatient preferencesPatientsTrial dataEnd pointTrial resultsEndpointMACECABGSurgeryTrialsStructured toolDeathStudy dataRevascularisation
2013
Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
Ahmad Y, Lip GY, Lane DA. Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. Canadian Journal Of Cardiology 2013, 29: s4-s13. PMID: 23790597, DOI: 10.1016/j.cjca.2013.03.009.Peer-Reviewed Original ResearchConceptsDevelopment of AFAtrial fibrillationRisk factorsStroke riskAF patientsOccurrence of AFEffective oral anticoagulationAcute cardiac conditionsCause of strokeLow-risk patientsNovel risk factorsNovel therapeutic targetPublic health consequencesFormal anticoagulationOral anticoagulationRisk patientsPatient cohortCardiac conditionsEpidemic proportionsTherapeutic targetClinical practicePatientsAnticoagulationHealth consequencesRisk determinantsPreventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke risk
2012
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original Research